NASDAQ:MLAB - Mesa Laboratories Stock Price, Forecast & News

Mesa Laboratories trades on the NASDAQ under the ticker symbol "MLAB."

Mesa Laboratories announced a quarterly dividend on Thursday, January 9th. Stockholders of record on Friday, February 28th will be given a dividend of $0.16 per share on Monday, March 16th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.24%. The ex-dividend date is Thursday, February 27th. View Mesa Laboratories' Dividend History.

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced its quarterly earnings data on Monday, February, 10th. The medical instruments supplier reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of $0.88 by $1.94. The medical instruments supplier had revenue of $31.66 million for the quarter, compared to analyst estimates of $31.05 million. Mesa Laboratories had a net margin of 4.03% and a return on equity of 10.14%. View Mesa Laboratories' Earnings History.

Mesa Laboratories is scheduled to release their next quarterly earnings announcement on Monday, June 1st 2020. View Earnings Estimates for Mesa Laboratories.

3 analysts have issued 12 month price targets for Mesa Laboratories' stock. Their forecasts range from $250.00 to $275.00. On average, they anticipate Mesa Laboratories' share price to reach $262.50 in the next twelve months. This suggests that the stock has a possible downside of 2.6%. View Analyst Price Targets for Mesa Laboratories.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesa Laboratories in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mesa Laboratories.

Headlines about MLAB stock have been trending very positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Mesa Laboratories earned a news sentiment score of 3.1 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Mesa Laboratories.

Some companies that are related to Mesa Laboratories include Cognex (CGNX), FLIR Systems (FLIR), National Instruments (NATI), Coherent (COHR), Itron (ITRI), Badger Meter (BMI), OSI Systems (OSIS), FARO Technologies (FARO), MTS Systems (MTSC), Vishay Precision Group (VPG) and Daktronics (DAKT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Micron Technology (MU), Altria Group (MO), Exxon Mobil (XOM), Coupa Software (COUP), Gilead Sciences (GILD) and PepsiCo (PEP).

Mesa Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (10.22%), Royce & Associates LP (6.09%), Kayne Anderson Rudnick Investment Management LLC (3.63%), State Street Corp (3.33%), Artisan Partners Limited Partnership (2.05%) and Renaissance Technologies LLC (1.51%). Company insiders that own Mesa Laboratories stock include Brian David Archbold, David M Kelly, Evan Guillemin, H Stuart Campbell, John Bradley Schmieder, John James Sullivan, John Sakys, Michael T Brooks, Robert V Dwyer and Seg Ventures, Llc. View Institutional Ownership Trends for Mesa Laboratories.

MLAB stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Marshall Wace LLP, Renaissance Technologies LLC, King Luther Capital Management Corp, THB Asset Management, SG Americas Securities LLC, Castleark Management LLC and Conestoga Capital Advisors LLC. Company insiders that have sold Mesa Laboratories company stock in the last year include Brian David Archbold, David M Kelly, Evan Guillemin, John Bradley Schmieder and Robert V Dwyer. View Insider Buying and Selling for Mesa Laboratories.

MLAB stock was bought by a variety of institutional investors in the last quarter, including Moody Aldrich Partners LLC, Royce & Associates LP, Thrivent Financial for Lutherans, Artisan Partners Limited Partnership, Russell Investments Group Ltd., Bank of New York Mellon Corp, Kayne Anderson Rudnick Investment Management LLC and Foundry Partners LLC. View Insider Buying and Selling for Mesa Laboratories.

Shares of MLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MLAB stock can currently be purchased for approximately $269.48.

Mesa Laboratories has a market capitalization of $1.18 billion and generates $103.14 million in revenue each year. The medical instruments supplier earns $7.48 million in net income (profit) each year or $5.37 on an earnings per share basis. Mesa Laboratories employs 366 workers across the globe.View Additional Information About Mesa Laboratories.

The official website for Mesa Laboratories is http://www.mesalabs.com/.

Mesa Laboratories' mailing address is 12100 W 6TH AVE, LAKEWOOD CO, 80228. The medical instruments supplier can be reached via phone at 303-987-8000 or via email at [email protected]